Login to Your Account



Clinic Roundup


Monday, July 8, 2013
• Cell Therapeutics Inc., of Seattle, said an article summarizing preclinical and clinical data, including pharmacology and pharmacokinetics, safety and efficacy data in Phase I and Phase II studies in myelofibrosis and lymphoma, for pacritinib, an oral JAK2/FLT3 inhibitor, was published in Drugs of the Future.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription